Hin Sang Group (International) Holding Co. Ltd.(6893.HK)
No price history available.
Key financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | HKDm | 119 | 121 | 81 | 93 | 92 | 105 | N/A | N/A |
| Operating profit | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | HKDm | -32 | -12 | -49 | -37 | -49 | -46 | N/A | N/A |
| EPS reported | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | HKDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | HKD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in HKD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hin Sang Group (International) Holding Co. Ltd., founded in 1996 and headquartered in Tsim Sha Tsui, Hong Kong, functions as a subsidiary of Genwealth Group Holding Company Limited. The company's core business revolves around developing, promoting, and selling healthcare products, with a particular emphasis on offerings for children, primarily serving the markets of Hong Kong and Mainland China. Its operations are strategically organized into four principal segments: 1. Product Development: This division focuses on creating and commercializing personal care products, household goods, and health supplements under proprietary brand names such as Hin Sang, Tai Wo Tong, Cheers Smart, Care Plus, Shuang Long, and King's Antiseptic. 2. Brand Development and Management: This unit specializes in the marketing, sales, distribution, logistics, and delivery of personal care products for brands including Pahmi, Enear, Vcnic, Zici, and Sunew, while also offering brand management and development services to other brand owners. 3. Trading of Goods: This segment handles the distribution and sale of skincare, personal care, and household products, procured from diverse sources like authorized dealers, independent traders, manufacturers, parallel importers, and various suppliers. 4. Healthcare: This division provides traditional Chinese medical services tailored for mothers and children, in addition to developing maternal and child health-related products and operating medical centers and hospitals. Beyond these primary activities, the group also engages in the trade of skincare, personal care, and slimming products, as well as property holding. The company's products are available to consumers directly in Hong Kong, through a robust distribution network spanning the People's Republic of China and Macau, and via online platforms.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hin Sang Group (International) Holding Co. Ltd. (6893.HK)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Hin Sang Group (International) Holding Co. Ltd., founded in 1996 and headquartered in Tsim Sha Tsui, Hong Kong, functions as a subsidiary of Genwealth Group Holding Company Limited. The company's core business revolves around developing, promoting, and selling healthcare products, with a particular emphasis on offerings for children, primarily serving the markets of Hong Kong and Mainland China. Its operations are strategically organized into four principal segments: 1. Product Development: This division focuses on creating and commercializing personal care products, household goods, and health supplements under proprietary brand names such as Hin Sang, Tai Wo Tong, Cheers Smart, Care Plus, Shuang Long, and King's Antiseptic. 2. Brand Development and Management: This unit specializes in the marketing, sales, distribution, logistics, and delivery of personal care products for brands including Pahmi, Enear, Vcnic, Zici, and Sunew, while also offering brand management and development services to other brand owners. 3. Trading of Goods: This segment handles the distribution and sale of skincare, personal care, and household products, procured from diverse sources like authorized dealers, independent traders, manufacturers, parallel importers, and various suppliers. 4. Healthcare: This division provides traditional Chinese medical services tailored for mothers and children, in addition to developing maternal and child health-related products and operating medical centers and hospitals. Beyond these primary activities, the group also engages in the trade of skincare, personal care, and slimming products, as well as property holding. The company's products are available to consumers directly in Hong Kong, through a robust distribution network spanning the People's Republic of China and Macau, and via online platforms.